A number of research firms have changed their ratings and price targets for Cigna Corporation (NYSE: CI):

  • 8/9/2017 – Cigna Corporation had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $185.00 price target on the stock.
  • 8/8/2017 – Cigna Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cigna’s shares have outperformed the industry, year to date. The company’s second-quarter 2017 earnings beat the Zacks Consensus Estimate and increased year over year, reflecting strong contribution from each of the company’s business segments. The company is poised for long-term growth on the back of its robust Global Supplemental business, growing Government business and increasing membership. A strong capital position and resumption of share buyback are the other positives. Cigna is engaged in a legal tussle with Anthem and thus the termination fee and other charges that it were to receive from the latter remain uncertain.  Increase in benefits and expenses continue to bother us.”
  • 8/7/2017 – Cigna Corporation had its price target raised by analysts at Deutsche Bank AG from $180.00 to $190.00. They now have a “buy” rating on the stock.
  • 8/7/2017 – Cigna Corporation had its price target raised by analysts at Morgan Stanley from $184.00 to $188.00. They now have an “overweight” rating on the stock.
  • 8/7/2017 – Cigna Corporation had its price target raised by analysts at Citigroup Inc from $185.00 to $198.00. They now have a “buy” rating on the stock.
  • 8/4/2017 – Cigna Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $190.00 price target on the stock, down previously from $199.00. They wrote, “CI reported Q2:17 adjusted EPS of $2.91 (GAAP $3.15), compared to OPCO’s estimate of $2.46 and Street consensus of $2.45. Adjusted results exclude $0.13 of realized investment gains and $0.18 from merger-related tax benefits, offset by $0.07 of amortization expense. The beat was driven by the Healthcare segment, with the Commercial MCR of 78.7% outperforming OPCO/Street estimates by 200/160 bps. Due to the beat, the company raised FY2017 EPS guidance to $9.75-$10.05 vs. $9.35-$9.85, with all three segment outlooks growing by $15-$40M.””
  • 8/4/2017 – Cigna Corporation had its “buy” rating reaffirmed by analysts at Credit Suisse Group. They now have a $196.00 price target on the stock.
  • 7/31/2017 – Cigna Corporation was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/28/2017 – Cigna Corporation had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $175.00 price target on the stock.
  • 7/26/2017 – Cigna Corporation was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 7/24/2017 – Cigna Corporation had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $182.00 price target on the stock.
  • 7/20/2017 – Cigna Corporation was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 7/14/2017 – Cigna Corporation had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $193.00 price target on the stock, up previously from $190.00.
  • 7/13/2017 – Cigna Corporation had its price target raised by analysts at Deutsche Bank AG from $175.00 to $180.00. They now have a “buy” rating on the stock.
  • 6/23/2017 – Cigna Corporation had its price target raised by analysts at Bank of America Corporation from $193.00 to $198.00. They now have a “buy” rating on the stock.
  • 6/22/2017 – Cigna Corporation had its price target raised by analysts at Royal Bank Of Canada from $177.00 to $182.00. They now have an “outperform” rating on the stock.
  • 6/22/2017 – Cigna Corporation had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $193.00 price target on the stock, up previously from $186.00.
  • 6/19/2017 – Cigna Corporation had its “market perform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $174.00 price target on the stock, up previously from $163.00.
  • 6/15/2017 – Cigna Corporation had its price target raised by analysts at Oppenheimer Holdings, Inc. from $174.00 to $185.00. They now have an “outperform” rating on the stock.
  • 6/15/2017 – Cigna Corporation had its price target raised by analysts at CIBC from $174.00 to $185.00. They now have an “outperform” rating on the stock.
  • 6/13/2017 – Cigna Corporation had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $177.00 price target on the stock.
  • 6/12/2017 – Cigna Corporation is now covered by analysts at Credit Suisse Group. They set an “outperform” rating and a $185.00 price target on the stock.

Cigna Corporation (NYSE:CI) opened at 175.36 on Friday. The stock has a market cap of $44.15 billion, a price-to-earnings ratio of 20.23 and a beta of 0.46. The firm has a 50-day moving average price of $172.11 and a 200 day moving average price of $158.96. Cigna Corporation has a 1-year low of $115.03 and a 1-year high of $178.57.

Cigna Corporation (NYSE:CI) last issued its quarterly earnings results on Friday, August 4th. The health services provider reported $2.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.48 by $0.43. The company had revenue of $10.32 billion for the quarter, compared to the consensus estimate of $10.26 billion. Cigna Corporation had a return on equity of 17.40% and a net margin of 7.46%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same period last year, the business posted $1.98 earnings per share. On average, equities research analysts anticipate that Cigna Corporation will post $10.00 EPS for the current fiscal year.

In other news, Director Jane E. Md Henney sold 600 shares of the firm’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $174.14, for a total value of $104,484.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David Cordani sold 153,168 shares of the firm’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $170.20, for a total value of $26,069,193.60. Following the completion of the sale, the chief executive officer now directly owns 421,162 shares in the company, valued at $71,681,772.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 261,014 shares of company stock worth $44,434,114. 1.30% of the stock is currently owned by company insiders.

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Receive News & Ratings for Cigna Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.